Boron neutron capture therapy for clear cell sarcoma (CCS): biodistribution study of p-borono-L-phenylalanine in CCS-bearing animal models

T Andoh,T Fujimoto,T Sudo,I Fujita,M Imabori,H Moritake,T Sugimoto,Y Sakuma,T Takeuchi,S Kawabata,M Kirihata,T Akisue,K Yayama,M Kurosaka,S Miyatake,Y Fukumori,H Ichikawa

DOI: https://doi.org/10.1016/j.apradiso.2011.02.005

Abstract:Clear cell sarcoma (CCS) is a rare melanocytic malignant tumor with a poor prognosis. Our previous study demonstrated that in vitro cultured CCS cells have the ability to highly uptake l-BPA and thus boron neutron capture therapy could be a new option for CCS treatment. This paper proved that a remarkably high accumulation of (10)B (45-74 ppm) in tumor was obtained even in a CCS-bearing animal with a well-controlled biodistribution followed by intravenous administration of L-BPA-fructose complex (500 mg BPA/kg).